R Squared’s Rani Therapeutics RANI Stock Holding History

R Squared’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,170	Closed	-$2.97K	–	1206
2024 Q4	$2.97K	Buy	+2,170	New	+$4.56K	﹤0.01%	1413

Other funds holding RANI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

USAA

United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KPWS

Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

R Squared's RANI Position: Q1 2025 in Review

R Squared sold out of Rani Therapeutics (RANI) in Q1 2025, closing a stake of 2,170 shares — an estimated $2.97K sold.

R Squared first reported a position in RANI in Q4 2024 and held it in 1 quarter. The position peaked at $2.97K in Q4 2024. 38 funds tracked by Wall St. Rank hold RANI as of Q1 2025.

R Squared reported no remaining Rani Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,170 Rani Therapeutics shares in Q1 2025, an estimated $2.97K.
R Squared first reported a position in Rani Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Rani Therapeutics position peaked at $2.97K in Q4 2024.
38 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.